Hartmann L C, Marschke R F, Schaid D J, Ingle J N
Division of Medical Oncology, Mayo Clinic Scottsdale, Arizona.
Mayo Clin Proc. 1991 Aug;66(8):805-13. doi: 10.1016/s0025-6196(12)61198-7.
Currently, the role of adjuvant systemic therapy in women with node-negative breast cancer is being determined. Several studies of adjuvant hormonal therapy and adjuvant chemotherapy have demonstrated a moderate reduction in the risk of recurrence in the treated patients. With relatively limited follow-up, however, overall survival has not improved with use of adjuvant therapy. The use of prognostic factors to select those patients at highest risk for relapse is an active area of oncologic research. The decision to recommend adjuvant therapy necessitates assessment of the probability of recurrence, the expected reduction of risk with adjuvant therapy, the toxic effects of therapy, and the influence of treatment on the patient's overall quality of life.
目前，辅助性全身治疗在淋巴结阴性乳腺癌女性患者中的作用正在确定。多项辅助性激素治疗和辅助性化疗研究表明，接受治疗的患者复发风险有一定程度降低。然而，由于随访时间相对有限，辅助治疗并未改善总体生存率。利用预后因素来选择那些复发风险最高的患者是肿瘤学研究的一个活跃领域。推荐辅助治疗的决策需要评估复发概率、辅助治疗预期的风险降低程度、治疗的毒性作用以及治疗对患者总体生活质量的影响。
